Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 1, 2020

PCI Pharma Service Launches Digital Platform for Supply Chain Management

pci | bridge makes inventory, production, distribution, and shipping data immediately accessible by integrating the platform with PCI’s other systems, making the data manageable from both sides.

PCI Pharma Services, a drug development solutions company based in Philadelphia, PA, announced on Sept. 28, 2020 that it has launched pci | bridge, a digital platform that provides customers with real-time clinical and commercial supply chain data and insights.

According to a company press release, the platform makes inventory, production, distribution, and shipping data immediately accessible by integrating the platform with PCI’s other systems, making the data manageable from both sides. The platform also comes equipped with a document repository for the storage of electronic paperwork.

“At PCI, we are always looking to the future and could see the potential that technology and digital systems held for the pharmaceutical supply chain industry,” said Salim Haffar, CEO, PCI Pharma Services, in the press release. “Twelve months ago, we made the deliberate decision as an organization to invest more in this area, with the goal of enhancing client experiences, digitizing business processes, and aligning our IT to scale as we grow. The launch of pci | bridge represents a key milestone achievement in our digital transformation journey. We believe our unique offering will simplify how our clients interact with us and create a leading-edge client experience.”

“Having a fully functioning supply chain, whose foundation is built on digitally-enabled capabilities and technologies, means we can be more adept at moving resources, assets and inventory – quickly and effectively,” said Wayne Hull, chief digital and technology officer, PCI Pharma Services, in the press release. “We are embracing new technologies at PCI because they improve client experiences, give greater visibility into the supply chain, and provide data insights to optimize efficiencies and mitigate risks.”

Source: ​ PCI​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.